/
Infectious Disease
Malaria
62
Pipeline Programs↗
72
Active Trials↗
26
Companies Involved↗
Malaria is a moderately active landscape with 62 programs across 26 companies. The most active players are GSK, Eisai. 12 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical40
Phase 15
Phase 25
Phase 312
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
39 of 46 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 94% of 62 pipeline programs.
Analysis
Trial Status
603
clinical trials
Completed442 · 73%
Unknown status46 · 8%
Recruiting27 · 4%
Not yet recruiting26 · 4%
Terminated26 · 4%
Active, not recruiting18 · 3%
Other18 · 3%
Clinical Trials
Trial Activity
603 trials
Evaluation, Treatment, and Monitoring of Patients With Known or Suspected Parasitic Infection
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001645·800 enrolled
Phase 1 Study of Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT06607003·300 enrolled
In-Vitro Testing of Pregnancy Malaria Vaccine Candidates
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT02471378·7,476 enrolled
Page 1 of 41
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)